Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Ralph Snyderman, insider at CareDx

Ralph Snyderman Insider Information

Director of CareDx
Ralph Snyderman has served as a member of our board of directors since May 2005. Dr. Snyderman has held the position of chancellor emeritus and James B. Duke Professor of Medicine at Duke University since July 2004. From January 1989 to June 2004, he served as chancellor for health affairs at the Duke University School of Medicine, and was the founding CEO and president of the Duke University Health System. From January 2006 to November 2009, he consulted for New Enterprise Associates, a venture capital firm, as a venture partner. He previously served on the boards of directors of The Procter & Gamble Company, Pharmaceutical Product Development, LLC (PPD), Trevena, Inc., Crescendo Bioscience, Inc. and Targacept, Inc. He currently serves on the boards of Nodality, Inc., Press Ganey Associates, Inc., and Liquida Technologies, Inc. Dr. Snyderman is a member of the Association of American Physicians, where he served as president from 2003 to 2004, the Association of American Medical Colleges, where he served as chair from 2001 to 2002, the Institute of Medicine, and the American Academy of Arts & Sciences. Dr. Snyderman holds a BS in pre-medical studies from Washington College, an MD from the State University of New York, Downstate Medical Center, and completed an internship and residency in Medicine at Duke University.

What is Ralph Snyderman's net worth?

The estimated net worth of Ralph Snyderman is at least $1.51 million as of May 28th, 2021. Dr. Snyderman owns 58,549 shares of CareDx stock worth more than $1,514,077 as of May 22nd. This net worth estimate does not reflect any other assets that Dr. Snyderman may own. Learn More about Ralph Snyderman's net worth.

How do I contact Ralph Snyderman?

The corporate mailing address for Dr. Snyderman and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected] Learn More on Ralph Snyderman's contact information.

Has Ralph Snyderman been buying or selling shares of CareDx?

Ralph Snyderman has not been actively trading shares of CareDx during the past quarter. Most recently, on Sunday, May 22nd, 0 shares of BMO Capital Markets stock. Learn More on Ralph Snyderman's trading history.

Who are CareDx's active insiders?

CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director). Learn More on CareDx's active insiders.

Are insiders buying or selling shares of CareDx?

In the last twelve months, CareDx insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $211,700.00. In the last twelve months, insiders at the sold shares 39 times. They sold a total of 350,011 shares worth more than $18,189,360.58. The most recent insider tranaction occured on May, 11th when Director Grace Colon sold 5,179 shares worth more than $119,168.79. Insiders at CareDx own 4.6 % of the company. Learn More about insider trades at CareDx.

Information on this page was last updated on 5/11/2022.

Ralph Snyderman Insider Trading History at CareDx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2021Sell2,512$77.30$194,177.6058,549View SEC Filing Icon  
5/28/2021Sell2,511$81.08$203,591.8858,549View SEC Filing Icon  
1/15/2021Sell12,000$88.88$1,066,560.0072,672View SEC Filing Icon  
See Full Table

Ralph Snyderman Buying and Selling Activity at CareDx

This chart shows Ralph Snyderman's buying and selling at CareDx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CareDx Company Overview

CareDx logo
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $25.86
Low: $24.25
High: $26.26

50 Day Range

MA: $33.07
Low: $21.70
High: $40.92

2 Week Range

Now: $25.86
Low: $21.25
High: $96.88

Volume

487,305 shs

Average Volume

939,791 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.